Quarterly revenue growth rates and guidance - market expects sustained 20-30%+ growth to justify valuation; any deceleration triggers selloffs
New product launches and FDA clearances - particularly in higher-margin spine segment or international expansion products
Acquisition announcements - KIDS has been serial acquirer of pediatric portfolios (Orthex, Vilex, Telos); integration success and revenue synergies drive sentiment
Surgeon adoption metrics and sales force productivity - new surgeon adds and revenue per rep indicate market penetration progress
low-to-moderate - Pediatric orthopedic procedures are largely non-discretionary (trauma from accidents, progressive scoliosis requiring intervention), providing recession resilience. However, elective procedures like limb lengthening or early-stage deformity corrections may see modest deferrals during economic stress when families face insurance coverage gaps or high-deductible plans. Hospital capital equipment budgets can tighten in recessions, potentially slowing instrument set placements. Overall, the medically necessary nature of most pediatric orthopedic surgeries insulates revenue from GDP fluctuations more than adult elective orthopedics.
Rising rates create moderate headwinds through two channels: (1) Higher cost of capital pressures valuation multiples for unprofitable growth companies - KIDS trades on forward revenue multiples given negative earnings, making it sensitive to discount rate changes. (2) Modest impact on hospital capital budgets as borrowing costs increase for facility expansions or equipment purchases. However, the company's strong current ratio of 7.40 and low debt/equity of 0.28 minimize direct financing cost impacts. The primary sensitivity is valuation compression as investors rotate from growth to profitable value stocks when rates rise.
Reimbursement pressure from government and commercial payers - CMS and private insurers increasingly scrutinize orthopedic implant pricing; bundled payment models could compress hospital willingness to pay premium prices for pediatric-specific devices versus adapted adult products
Limited addressable market size - pediatric orthopedics represents <5% of total orthopedic market; only ~3,000 specialized surgeons globally limits ultimate revenue ceiling compared to adult-focused competitors with 10x larger TAMs
Regulatory pathway complexity - pediatric device approvals face additional scrutiny and longer timelines; any FDA enforcement changes or safety concerns in orthopedic implants could delay product launches
growth - Investors are paying 1.9x price/sales for a company with 37.6% revenue growth but negative profitability, indicating growth-at-reasonable-price (GARP) positioning. The stock attracts healthcare specialists focused on niche medical device plays with defensible market positions and long-term operating leverage stories. Not suitable for value investors given negative earnings, nor income investors given no dividend. The -30.7% one-year return suggests momentum investors have exited, leaving fundamental long-term holders focused on the 2027-2028 profitability inflection story.
Trend
-13.1% vs SMA 50 · -19.8% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $234.9M $234.1M–$235.7M | — | -$1.25 | — | ±0% | Moderate3 |
FY2026(current) | $265.2M $264.9M–$265.6M | ▲ +12.9% | -$1.18 | — | ±0% | High6 |
FY2027 | $296.7M $296.2M–$297.2M | ▲ +11.9% | -$0.81 | — | ±0% | High6 |
New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights l…
orthopediatrics is the worldwide leader in pediatric orthopedics. we are the first company whose total focus is helping children with orthopaedic conditions and injuries by providing the surgeons who care for them with anatomically appropriate implants. every day, we focus purely on advancing the field of pediatric orthopedics through the innovative development of state-of-the-art technologies, commitment to quality products, and industry-leading support and clinical education with our experienced team of experts. our offering is continuing to expand as we strive to develop all of the necessary implants and instruments that a pediatric orthopedic surgeon needs to treat his/her patients, including: long bone deformity correction & trauma, spine, and sports medicine. as we continue to grow, we are looking for talented professionals to join our cause! visit our website to learn more about current openings, or submit a resume to careers@orthopediatrics.com!
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
KIDS◀ | $15.65 | +3.78% | $401M | — | +1544.5% | -1677.5% | 1500 |
| $68.56 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $513.72 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $87.60 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $183.72 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $206.53 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $74.81 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.04% | — | 40.5 | +342129.4% | -3665.5% | 1500 |